DocumentNHS8002.docx NHS8002 Ethical Challenges Capella University NHS8002 Preventing Opioid Addiction Unfortunately, there has been a rise in death cases within the US over the years associated with individuals who
...
DocumentNHS8002.docx NHS8002 Ethical Challenges Capella University NHS8002 Preventing Opioid Addiction Unfortunately, there has been a rise in death cases within the US over the years associated with individuals who suffer from opioid misuse and addiction. In fact, œ600,000 deaths are related to opioids from the year 2000-2016. (Baird, 2018, p.145) Importance has been put on this issue as result of the high number of patients continually rising of those who are at higher risk for overdose and development of opioid addiction. Studies have been derived to give insight on risk factors associated to adults who suffer from prescription opioid misuse, addiction and overdose. Prescribing of opioids has become a progressively applied routine as they are recommended treatment of moderate to severe acute pain. Therefore, attention from government and regulatory agencies has increased with the hopes of combating this issue. These agencies have provided grants to help support community/state-based prevention efforts such as education for prescribers and patients, opioid overdose prevention and surveillance activities/programs. Interprofessional Coalition/Collaboration Firstly, the health of the public isn™t the responsibility of one individual or organization. It is the responsibility of the individual, caregivers, community, local businesses, charities and public services etc. Interprofessional coalition/collaboration is designed to improve patient outcomes through disease prevention and cure. A g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]